drugset
drugset / Trial / NCT01154452

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

NCT01154452 ↗

Phase 1/2 Completed 78 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating patients with advanced or metastatic sarcoma. Vismodegib may slow the growth of tumor cells. Gamma-secretase/notch signalling pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vismodegib together with gamma-secretase/notch signalling pathway inhibitor RO4929097 may be an effective treatment for sarcoma.

Timeline

Start
2010-06
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject RG4733 Small molecule — Oral
Subject Vismodegib Small molecule — Oral

Indications

Ewing sarcoma/peripheral primitive neuroectodermal tumor Kaposi's sarcoma adult epithelioid sarcoma adult extraskeletal osteosarcoma adult fibrosarcoma adult liposarcoma adult malignant mesenchymoma alveolar soft part sarcoma chondrosarcoma clear cell sarcoma of kidney dermatofibrosarcoma protuberans desmoplastic small round cell tumor epithelioid hemangioendothelioma extraskeletal myxoid chondrosarcoma gastrointestinal stromal tumor malignant peripheral nerve sheath tumor ovarian sarcoma rhabdomyosarcoma small intestine leiomyosarcoma synovial sarcoma undifferentiated pleomorphic sarcoma uterine corpus sarcoma